Amyloid-beta (A-beta) aggregates are tangles of proteins most notably associated with neurodegenerative diseases like Alzheimer's. Despite its constant stint in the limelight, however, researchers ...

Scientists from St Petersburg University and the University of Montpellier have developed the first software enabling the prediction of pairs of proteins in amyloid fibrils capable of co-aggregation, ...

Researchers have developed a microscopy technique to visualize amyloid beta’s underlying structure, which could yield new insights into Alzheimer’s disease. As the prevalence of Alzheimer’s rises, ...

After studying 140,000 versions of the Aβ42 peptide, scientists identified some of the earliest molecular interactions that drive the formation of harmful amyloid protein aggregates found in Alzheimer ...

A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...

For the first time, scientists have unraveled the structure of proteins in the brains of patients with Alzheimer's disease. The findings provide clues into how these disease-causing proteins interact ...

On July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or Kisunla, is the third drug approved to target one of the causes of ...

Alzheimer's disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The ...